A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Amyloidosis
- Focus Adverse reactions
- 06 Dec 2016 Updated results (data cutoff 23 Jun 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Jul 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 12 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.